{"id":7237,"date":"2025-07-02T18:20:55","date_gmt":"2025-07-02T23:20:55","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=7237"},"modified":"2025-07-13T15:09:02","modified_gmt":"2025-07-13T20:09:02","slug":"nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 una investigaci\u00f3n innovadora en la reuni\u00f3n anual de la ASGCT de 2025."},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"row\">\n<div class=\"col-sm-12\">\n<div class=\"row detail-headline\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2 class=\"prntac\" style=\"text-align: center;\"><i>Las presentaciones destacar\u00e1n la durabilidad, la eficacia y la seguridad de las plataformas de terapia optogen\u00e9tica de Nanoscope.<\/i><\/h2>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">12 de mayo de 2025<\/span><\/span>\u00a0\/PRNewswire\/ \u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy m\u00faltiples presentaciones en el 28<sup>th<\/sup>\u00a0reuni\u00f3n anual de la Sociedad Americana de Terapia G\u00e9nica y Celular (<a href=\"https:\/\/annualmeeting.asgct.org\/?gad_source=1&gad_campaignid=22011672452&gbraid=0AAAAADHZ2HQnr1TF8BjiisdZLSvQ1L5fH&gclid=Cj0KCQjwrPHABhCIARIsAFW2XBOyOPUxQcyc0OwCQ59sxmSlG0uS4eBLOykckVLfPmHO9pLdEk1Gv2waAqPOEALw_wcB\" target=\"_blank\" rel=\"nofollow noopener\">ASGCT 2025<\/a>), que se celebrar\u00e1 en el Centro de Convenciones Ernest N. Morial en\u00a0<span class=\"xn-location\">Nueva Orleans<\/span>,\u00a0<span class=\"xn-chron\">Del 13 al 17 de mayo<\/span><sup>th<\/sup>, 2025. Las presentaciones de Nanoscope se centrar\u00e1n en la empresa.\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/technology-2\/\" target=\"_blank\" rel=\"nofollow noopener\">Terapia optogen\u00e9tica MCO-010<\/a>\u00a0para enfermedades degenerativas de la retina. MCO-010 es el programa m\u00e1s avanzado en la plataforma MCO (opsina multicaracter\u00edstica) y la primera y \u00fanica terapia independiente de mutaciones.\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">Se ha demostrado que restaura la visi\u00f3n en pacientes con retinosis pigmentaria avanzada.<\/a>\u00a0mediante una inyecci\u00f3n intrav\u00edtrea est\u00e1ndar de una sola vez.<\/p>\n<p>\u201cNos complace presentar los resultados de seguridad y eficacia de nuestra terapia MCO para m\u00faltiples enfermedades de la retina, incluida la degeneraci\u00f3n macular de Stargardt en ensayos cl\u00ednicos y la atrofia geogr\u00e1fica en modelos de primates no humanos\u201d, dijo el Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>, cofundador y presidente de Nanoscope.\u201c<b>Adem\u00e1s de presentar ensayos robustos para garantizar la potencia de MCO-010<\/b>, Esperamos compartir detalles sobre los beneficios terap\u00e9uticos positivos observados en pacientes con enfermedad de Stargardt, que fueron similares a los efectos duraderos.\u00a0<b>Mejora de la visi\u00f3n en pacientes con retinosis pigmentaria (RP).\u00a0<\/b>Es un momento emocionante en Nanoscope, ya que estamos preparando MCO-010 para su comercializaci\u00f3n, incluyendo la presentaci\u00f3n de la solicitud de licencia biol\u00f3gica (BLA).\u201d<\/p>\n<p>A continuaci\u00f3n se detallan las presentaciones de la reuni\u00f3n:<\/p>\n<p><a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4425505-1&h=1073963099&u=https%3A%2F%2Fannualmeeting.asgct.org%2Fprogram&a=Full+Agenda\" target=\"_blank\" rel=\"nofollow noopener\">Programa completo<\/a><\/p>\n<p>Presentaciones en el podio:<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Martes, 13 de mayo<\/span><sup>th<\/sup>, 14:15 \u2013\u00a0<span class=\"xn-chron\">14:30<\/span>;\u00a0<i>Habitaciones 265-268<\/i>\u00a0<\/b>- Dr.\u00a0<span class=\"xn-person\">Samarendra Mohanty<\/span>\u00a0presentando \u2013 \u201c<i>Seguridad y eficacia de la terapia g\u00e9nica con opsinas multicaracter\u00edsticas para mejorar la visi\u00f3n en un modelo de atrofia geogr\u00e1fica en primates no humanos.<\/i>\u201c<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Martes, 13 de mayo<\/span><sup>th<\/sup>,\u00a0<span class=\"xn-chron\">14:30<\/span>\u00a0\u2013\u00a0<span class=\"xn-chron\">14:45<\/span>;\u00a0<i>Habitaciones 288-290<\/i>\u00a0<\/b>- Dr.\u00a0<span class=\"xn-person\">Saurav Mohanty<\/span>\u00a0presentando \u2013 \u201c<i>Seguridad, tolerabilidad, biodistribuci\u00f3n, expresi\u00f3n de transgenes y eficacia de la administraci\u00f3n dirigida no viral mediante l\u00e1ser guiada por im\u00e1genes de opsina multicaracter\u00edstica en retinas de monos verdes africanos.<\/i>\u201c<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Mi\u00e9rcoles, 14 de mayo<\/span><sup>th<\/sup>,\u00a0<span class=\"xn-chron\">16:00<\/span>\u00a0\u2013\u00a0<span class=\"xn-chron\">16:15<\/span>;\u00a0<i>Habitaciones 265-268<\/i><\/b>- Dr.\u00a0<span class=\"xn-person\">Subrata Batabyal<\/span>\u00a0presentando \u2013 \u201c<i>Desarrollo de ensayos de potencia ortogonales para la terapia g\u00e9nica con opsinas multicaracter\u00edsticas: expresi\u00f3n g\u00e9nica y actividad estimulada por la luz.<\/i>\u201c<\/li>\n<\/ul>\n<p>Presentaciones en formato p\u00f3ster:<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Martes, 13 de mayo<\/span><sup>th<\/sup>,\u00a0\u00a0<span class=\"xn-chron\">18:00<\/span>\u00a0\u2013\u00a0<span class=\"xn-chron\">19:30<\/span>;\u00a0<\/b><b>Sala de carteles\u00a0<\/b><b>\u2013<\/b>\u00a0Dr.\u00a0<span class=\"xn-person\">Vinit Mahajan<\/span>\u00a0Presentaci\u00f3n: \u201cAdministraci\u00f3n de c\u00e9lulas retinianas humanas de una prote\u00edna sint\u00e9tica bioingenierizada sensible a m\u00faltiples longitudes de onda de luz en pacientes con enfermedad de Stargardt\u201d, P\u00f3ster n.\u00b0 584<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Mi\u00e9rcoles, 14 de mayo<\/span><sup>th<\/sup>,\u00a0<span class=\"xn-chron\">5:30 pm<\/span>\u00a0\u2013\u00a0<span class=\"xn-chron\">19:00<\/span>;\u00a0<\/b><b>Sala de carteles\u00a0<\/b><b>\u2013<\/b>\u00a0Dr.\u00a0<span class=\"xn-person\">Amir Singh<\/span>\u00a0Presentaci\u00f3n: \u201cEstudios de degradaci\u00f3n forzada de un f\u00e1rmaco de terapia g\u00e9nica con opsina multicaracter\u00edstica\u201d, P\u00f3ster n.\u00b0 1380<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">Jueves, 15 de mayo<\/span><sup>th<\/sup>,\u00a0<span class=\"xn-chron\">5:30 pm<\/span>\u00a0\u2013\u00a0<span class=\"xn-chron\">19:00<\/span><\/b>;\u00a0<b>Sala de carteles\u00a0<\/b><b>\u2013<\/b>\u00a0Dr.\u00a0<span class=\"xn-person\">Ananta Ayyagari<\/span>\u00a0Presentaci\u00f3n: \u201cAprobaciones regulatorias aceleradas en terapia celular y g\u00e9nica\u201d, P\u00f3ster n.\u00b0 1856<\/li>\n<\/ul>\n<p>Los miembros del equipo de Nanoscope tambi\u00e9n estar\u00e1n disponibles para reuniones durante la conferencia ASGCT.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas, independientes de las mutaciones y que restauran la visi\u00f3n, para los millones de pacientes con ceguera causada por enfermedades degenerativas de la retina para las que actualmente no existe tratamiento. Tras los resultados positivos al final del estudio RESTORE, ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo de fase 2b para la RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en 2025. La compa\u00f1\u00eda ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>, Tambi\u00e9n en 2025. MCO-010 ha recibido las designaciones de v\u00eda r\u00e1pida de la FDA y la designaci\u00f3n de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un f\u00e1rmaco MCO-020 no viral administrado por l\u00e1ser, listo para la solicitud de nuevo f\u00e1rmaco en investigaci\u00f3n (IND), para la atrofia geogr\u00e1fica (GA), as\u00ed como un f\u00e1rmaco AAV para la amaurosis cong\u00e9nita de Leber, en estudios precl\u00ednicos.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Terap\u00e9utica del nanoscopio<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations will highlight durability, efficacy and safety of\u00a0Nanoscope\u2019s optogenetic therapy platforms DALLAS,\u00a0May 12, 2025\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced multiple presentations at the 28th\u00a0annual meeting of the American Society of Gene [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7181,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7237","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-02T23:20:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting\",\"datePublished\":\"2025-07-02T23:20:55+00:00\",\"dateModified\":\"2025-07-13T20:09:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg\",\"datePublished\":\"2025-07-02T23:20:55+00:00\",\"dateModified\":\"2025-07-13T20:09:02+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg\",\"width\":2560,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/02\\\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 una investigaci\u00f3n innovadora en la reuni\u00f3n anual de ASGCT 2025 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-07-02T23:20:55+00:00","article_modified_time":"2025-07-13T20:09:02+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting","datePublished":"2025-07-02T23:20:55+00:00","dateModified":"2025-07-13T20:09:02+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/"},"wordCount":567,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/05\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/","name":"Nanoscope Therapeutics presentar\u00e1 una investigaci\u00f3n innovadora en la reuni\u00f3n anual de ASGCT 2025 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/05\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg","datePublished":"2025-07-02T23:20:55+00:00","dateModified":"2025-07-13T20:09:02+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/05\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/05\/NSCOPE_ASGCT_LI_2025FEATURE-scaled-1.jpg","width":2560,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/02\/nanoscope-therapeutics-to-present-groundbreaking-research-at-asgct-2025-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Groundbreaking Research at ASGCT 2025 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=7237"}],"version-history":[{"count":1,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7237\/revisions"}],"predecessor-version":[{"id":7559,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/7237\/revisions\/7559"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/7181"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=7237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=7237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=7237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}